A recent study has found that a diabetes drug now at the center of Byetta lawsuit filings may reduce the heart attack risks of another medication.

The research, which was published in Science Translational Medicine this October, looked at data from the U.S. Food and Drug Administration (FDA)’s adverse event report database, which indicated that individuals using the incretin mimetic, Byetta, in combination with fellow diabetes drug Avandia, may be at a lowered risk for a heart attack than those who just took Avandia. The study was led by researchers from the Icahn School of Medicine at Mount Sinia, who analyzed the federal agency’s database and determined that incretin mimetics like Januvia, Victoza and Byetta may reduce blood clotting. Although this may serve as one advantage to taking this medication, which is prescribed to type-2 diabetics, the pancreatic side effects alleged in Byetta and Januvia lawsuit claims are dangerous in their own right.

Januvia, Byetta Pancreatic Cancer Concerns Rise with Each Passing Year

Byetta, Januvia, and other incretin mimetics have been the subject of rising concern from the U.S. Food and Drug Administration (FDA) in recent years. In addition to Byetta and Januvia’s involvement in more than 60 lawsuits filed in a federal multidistrict litigation established in the U.S. District Court, Southern District of California, it is estimated that 40 of these cases allege Byetta pancreatic cancer injuries.

The above-mentioned study is not the first time this drug has made headlines, however. After being brought to market in 2005, the FDA issued a public health alert in 2008 after receiving several pancreatitis reports in patients who took Byetta. Concerns were heightened three years later when a study published in a February 2011 report from Gastroenerology showed that users of this medication were at a 3-fold risk for pancreatic cancer, and may be six times more likely to develop pancreatitis than those taking other drugs. Thyroid cancer may also stem from use of Byetta, but that link has not been confirmed, the study suggests.

Contact a Byetta Lawyer to Learn More about Filing a Claim

If you were diagnosed with pancreatitis, pancreatic cancer or thyroid cancer after taking Byetta or another incretin mimetic, call the attorneys at Bernstein Liebhard LLP to learn more about the process of filing a lawsuit. The Firm can be reached at (877) 779-1414.

Published October 17, 2013 by